| 产品描述: | AT-007 is an orally active central nervous system (CNS) penetrant Aldose Reductase inhibitor for treatment of Galactosemia with an IC50 value of 100 pM. AT-007 reduces toxic galactitol levels and prevents disease complications in GALT deficiency rats |
| 靶点: |
IC50: 100 pM (Aldose Reductase);Reductase |
| 体内研究: |
AT-007 显着降低了 GALT 缺失大鼠的脏器组织(肝,脑和血浆)中半乳糖醇水平,但没有增加半乳糖或 Gal1P 的水平 |
| 参考文献: |
1. Maeve Conneighton, et al. Applied Therapeutics Announces Initiation of Phase 1/2 Study of AT-007 in Galactosemia. 2. UNITED STATES SECURITIES AND EXCHANGE COMMISSION. APPLIED THERAPEUTICS, INC. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.351 ml |
11.754 ml |
23.507 ml |
| 5 mM |
0.47 ml |
2.351 ml |
4.701 ml |
| 10 mM |
0.235 ml |
1.175 ml |
2.351 ml |
| 50 mM |
0.047 ml |
0.235 ml |
0.47 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |